Please assess the completion status of the following clinical trial:

Trial Title: Y90 Ibritumomab Tiuxetan Post R-CHOP Chemotherapy for Advanced Stage Follicular Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age greater than or equal to 18 years.~* Biopsy demonstration of a CD20+ follicular non-Hodgkin's lymphoma diagnosed according to the World Health Organization (WHO) classification (grade I, II, or IIIa).~* Staging demonstration of advanced stage disease (stage III or IV) according to the Ann Arbor staging system.~* Intermediate or high-risk prognostic score (2-5 points) according to the follicular lymphoma international prognostic index (FLIPI).~* Adequate performance status (less than or equal to 2) according to the Eastern Cooperative Oncology Group (ECOG) (Zubrod) scale.~* No prior radiotherapy or systemic therapy, including chemotherapy or immunotherapy (rituximab).~* Bi-dimensional measurable disease by physical examination or radiographic evaluation (disease measurements at least 1.5 cm x 1.5 cm) or assessable disease on bone marrow evaluation.~* Clinical criteria for therapeutic intervention, as previously reported by Hiddeman, including one of: the presence of B-symptoms, bulky disease (mediastinal lymphomas \>7.5 cm or other lymphomas \>5 cm in maximal diameter), an impairment of normal hematopoesis with hemoglobin \<10g/mm3, granulocytes \<1500/mm3, or platelets \<100,000/mm3, and/or a rapidly progressive disorder.~* Patient consent must be obtained according to the Sunnybrook Health Sciences Centre Research Ethics Board requirements. A sample consent form is given in Appendix I. The patient must sign the consent form prior to registration.~* Patients must be accessible for treatment and follow up. Patients registered on this trial must complete their therapy with 90Y Ibritumomab Tiuxetan at the participating centre. Induction chemotherapy with R-CHOP should also be completed at the participating centre, but exceptions can be made according to the discretion of the centre's primary investigator.~* Protocol treatment is to begin within 5 working days of patient registration~Exclusion Criteria:~* Pregnancy or women who intend to breast-feed during the study period.~* Follicular non-Hodgkin's lymphoma grade IIIb histology, according to the World Health Organization (WHO) classification.~* Known human immunodeficiency virus infection or hepatitis B viral infection.~* Life expectancy less than or equal to 3 months, according to physician judgement.~* Evidence of left ventricular (LV) dysfunction (ejection fraction less than or equal to 50%). Demonstration of LV function is required in patients over the age of 60 or in patients with a prior history of hypertension, congestive heart failure, peripheral vascular disease, cerebrovascular disease, coronary artery disease, or cardiac arrhythmia.~* Serum creatinine, alkaline phosphatase, or total bilirubin \>2.5 times the upper limit of the normal value, unless clearly related to lymphoma.~* Concurrent uncontrolled medical disease, including severe congestive heart failure, myocardial infarction within 6 months prior to enrollment, severe chronic renal failure, or active infection, with the severity of disease judged according to the discretion of the treating physician.~* Patients with a history of other malignancies, except: (1) adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or (2) other solid tumours curatively treated with no evidence of disease for \> 5 years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Y90 Ibritumomab Tiuxetan (Type: EXPERIMENTAL): Addition of Y90 Ibritumomab Tiuxetan RIT to CHOP-R treatment for follicular lymphoma-patients also receive maintenance Rituximab every 3 months for 2 years after the Y90 Ibritumomab Tiuxetan

Based on this trial design, predict the completion outcome and termination type (if applicable).